Wang Q.,Peking University |
Liu H.,Beijing Daopei Hospital |
Zhang X.,Beijing Daopei Hospital |
Liu Q.,Peking University |
And 4 more authors.
Blood | Year: 2010
Donor lymphocyte infusion is an alternative treatment for Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPDs) but with risk of graft-versushost diseases (GVHDs). According to the fetal-maternal microchimerism tolerance, we assumed that maternal lymphocyte infusion may be effective without causing GVHD. In 54 cases when a child required cytotherapy or hematopoietic stem cell transplantation, we studied the mother for child-mother microchimerism with use of insertion-deletion polymorphisms as allogeneic markers and a combination of nested polymerase chain reaction (PCR) and real-time quantitative PCR. Thirteen mothers were child-microchimerismpositive at the ratio of 10-5-10-3. Among them, 5 children had non-transplantassociated, EBV+ T-cell LPD. In these 5 cases, high doses of human leukocyte antigen-haploidentical maternal peripheral blood mononuclear cells (> 108/kg/infusion) were infused 1-4 times. Symptoms of all 5 patients improved between 3 and 10 days after the infusion; thereafter, 3 cases showed complete remission for 6-18 months without further therapy and 2 had partial remission. During the period of observation, none developed obvious GVHD. By quantitative PCR, in some patients maternal cells were found to be eliminated or decreased after infusions, indicating existence of host-versusgraft reaction. We suggest that high doses of mother's lymphocyte infusion may be an effective and safe treatment for nontransplant-associated EBV+ T-cell LPD. © 2010 by The American Society of Hematology.
Zhang Y.,Beijing Friendship Hospital |
Wang B.,Beijing Friendship Hospital |
Wang T.,ChinaJapan Friendship Hospital
Transplantation Proceedings | Year: 2010
De novo autoimmune hepatitis (AIH) occurred in patients who underwent liver transplantation for a different etiology. This 55-year-old woman was transplanted due to PBC. One year after liver transplantation, she complained of fatigue. Liver function tests showed markedly elevated serum alanine transaminase (ALT) and globulin levels. She also tested positive for anti-nuclear antibodies (ANA). Liver biopsy showed lymphocytic and plasmacytic infiltration in the portal and periportal areas, with numerous areas of bridging centrilobular necrosis, indicating AIH. She had a pretreatment AIH score of 16 points, and a posttreatment score of 18 points according to the scoring system of the International AIH Group (IAHG). The patient was treated effectively with prednisone, but then suffered two further episodes of AIH as a result of decreasing the prednisone dose. Histological features on liver biopsy were similar to those on initial presentation. Treatment with prednisone and azathioprine resulted in a dramatically improved outcome. Her liver function and globulin levels rapidly returned to normal and have remained so thereafter. © 2010 by Elsevier Inc. All rights reserved.
Zhu G.,Tsinghua University |
Wang Y.,Tsinghua University |
Huang B.,Tsinghua University |
Liang J.,Tsinghua University |
And 3 more authors.
Oncogene | Year: 2012
P21-activated kinase 1 (PAK1) is associated with colon cancer progression and metastasis, whereas the molecular mechanism remains elusive. Here, we show that downregulation of PAK1 in colon cancer cells reduces total Β-catenin level, as well as cell proliferation. Mechanistically, PAK1 directly phosphorylates Β-catenin proteins at Ser675 site and this leads to more stable and transcriptional active Β-catenin. Corroborating these results, PAK1 is required for full Wnt signaling, and superactivation of Β-catenin is achieved by simultaneous knockdown of adenomatous polyposis coli protein and activation of PAK1. Moreover, we show that Rac1 functions upstream of PAK1 in colon cancer cells and contributes to Β-catenin phosphorylation and accumulation. We conclude that a Rac1/PAK1 cascade controls Β-catenin S675 phosphorylation and full activation in colon cancer cells. Supporting this conclusion, overexpression of PAK1 is observed in 70% of colon cancer samples and is correlated with massive Β-catenin accumulation. © 2012 Macmillan Publishers Limited All rights reserved.
Chen-An P.,Cartilage Biology and Biomarkers |
Andreassen K.V.,Bone Biology and Pharmacology |
Henriksen K.,Bone Biology and Pharmacology |
Li Y.,Beijing Friendship Hospital |
And 2 more authors.
PLoS ONE | Year: 2012
Objective: Salmon calcitonin has chondroprotective effect both in vitro and in vivo, and is therefore being tested as a candidate drug for cartilage degenerative diseases. Recent studies have indicated that different chondrocyte phenotypes may express the calcitonin receptor (CTR) differentially. We tested for the presence of the CTR in chondrocytes from tri-iodothyronin (T3)-induced bovine articular cartilage explants. Moreover, investigated the effects of human and salmon calcitonin on the explants. Methods: Early chondrocyte hypertrophy was induced in bovine articular cartilage explants by stimulation over four days with 20 ng/mL T3. The degree of hypertrophy was investigated by molecular markers of hypertrophy (ALP, IHH, COLX and MMP13), by biochemical markers of cartilage turnover (C2M, P2NP and AGNxII) and histology. The expression of the CTR was detected by qPCR and immunohistochemistry. T3-induced explants were treated with salmon or human calcitonin. Calcitonin down-stream signaling was measured by levels of cAMP, and by the molecular markers. Results: Compared with untreated control explants, T3 induction increased expression of the hypertrophic markers (p<0.05), of cartilage turnover (p<0.05), and of CTR (p<0.01). Salmon, but not human, calcitonin induced cAMP release (p<0.001). Salmon calcitonin also inhibited expression of markers of hypertrophy and cartilage turnover (p<0.05). Conclusions: T3 induced early hypertrophy of chondrocytes, which showed an elevated expression of the CTR and was thus a target for salmon calcitonin. Molecular marker levels indicated salmon, but not human, calcitonin protected the cartilage from hypertrophy. These results confirm that salmon calcitonin is able to modulate the CTR and thus have chondroprotective effects. © 2012 Chen-An et al.
Sulkowski M.S.,Johns Hopkins University |
Cooper C.,Ottawa Hospital |
Hunyady B.,Kaposi Mor Teaching Hospital |
Jia J.,Beijing Friendship Hospital |
And 5 more authors.
Nature Reviews Gastroenterology and Hepatology | Year: 2011
HCV infects approximately 2-3% of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90% of patients; however, a major barrier to treatment uptake and delivery is the association of this therapy with frequent and, at times, serious adverse effects. Recognition and effective management of these adverse effects are critical components of the successful treatment of chronic HCV infection. In clinical trials, approximately 10-15% of patients discontinue Peg-IFN and ribavirin therapy due to adverse effects; however, in clinical practice, the rate of treatment discontinuation has been reported to be substantially higher. The off-target effect of Peg-IFN and ribavirin impacts most, if not all, organ systems; the most common adverse effects are hematologic, dermatologic, neurologic, immunologic, gastrointestinal, pulmonary, cardiovascular, and ocular. Regional and global variability exists in the nature of these adverse effects and the strategies employed to ameliorate their impact. This article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects. © 2011 Macmillan Publishers Limited. All rights reserved.
Kruger M.C.,Massey University |
Ha P.C.,Clinical Center and Basic Research |
Todd J.M.,Fonterra Brands Ltd |
Kuhn-Sherlock B.,Fonterra Research Center |
And 4 more authors.
European Journal of Clinical Nutrition | Year: 2012
Background/objectives:Risk for developing osteoporosis increases in Asia. The purpose of the study was to evaluate the impact of a high-calcium vitamin D fortified milk (HCM) intervention on parathyroid hormone (PTH) levels, vitamin D status and markers of bone turnover in postmenopausal Chinese women.Subjects/methods:Sixty three women (55 years) were assigned to receive two servings of either a calcium/vitamin D fortified milk or a control drink for 12 weeks. PTH, serum 25 (OH)D levels, C-telopeptide of type I collagen (CTX) levels and procollagen type I N-terminal propeptide (PINP) were measured at baseline, 2, 8 and 12 weeks of supplementation.Results:Daily calcium intake at baseline ranged between 260 and 482 mg for the HCM, and 252 and 692 mg for the control group. HCM improved serum 25 (OH)D levels significantly (33.13-39.49 nmol/l), while remaining similar in the control group (29.27-28.21 nmol/l). The difference between the groups were significant at week 2, 8 and 12. The percentage change in PTH levels in the HCM group was significant from week 2 onwards compared to the control drink (P0.017, P0.05 and P0.001 at weeks 2, 8 and 12, respectively). Plasma CTX of the HCM group reduced by 25% between weeks 0 and 2, remaining significantly lower and at similar levels up to week 12. The difference between the HCM and control group for PINP reached significance at weeks 8 (P0.011) and 12 (P0.003).Conclusions:The HCM intervention significantly improved vitamin D status and reduced bone turnover over 12 weeks in postmenopausal Chinese women. © 2012 Macmillan Publishers Limited.
Zhang F.,Beijing University of Technology |
Yang Z.,Beijing University of Technology |
Yang Z.,North University of China |
Cao M.,Beijing University of Technology |
And 10 more authors.
Cancer Letters | Year: 2014
The expression of miR-203 has been reported to be significantly down-regulated in esophageal cancer. We showed here that overexpression of miR-203 in esophageal cancer cells dramatically increased cell apoptosis and inhibited cell proliferation, migration and invasion as well as tumor growth and down-regulated miR-21 expression. We subsequently identified that small GTPase Ran was a target gene of miR-203. Furthermore, Ran restoration partially counteracted the tumor suppressive effects of miR-203 and increased miR-21 expression. Taken together, our findings suggest that miR-203 may act as novel tumor suppressor in esophageal cancer through down-regulating the expression of Ran and miR-21. © 2013 The Authors.
Sun G.,Jinan Military General Hospital |
Tang H.,Beijing Friendship Hospital |
Li M.,Jinan Military General Hospital |
Liu X.,Jinan Military General Hospital |
And 2 more authors.
European Spine Journal | Year: 2014
Purpose: The purpose of this study is to identify risk factors related to the development of subsequent fractures after vertebroplasty. Method: A retrospective study was conducted to review 175 patients with a 1-year follow-up who underwent vertebroplasty for first-time and single-level osteoporotic vertebral fractures. Subsequent fractures were diagnosed as recurrent intractable back pain, post-operatively correlated with MR image. Clinical parameters, such as age, gender, baseline VAS-score, lumbar bone mineral density (BMD) T-score, history of use of steroids, bisphosphonate therapy, symptom-free interval, the amount of bone cement injected, vacuum clefts, leakage of cement into the disk space, treated level and the changes of spinal geometry were recorded. Results: During the follow-up period, subsequent fractures developed in 37 (21.1 %) of 175 patients. Significant differences (P < 0.05) were found between the patients with subsequent fractures and the patients without subsequent fractures in regard to their BMD T-score, and treated vertebrae location. Average BMD T-score was -3.4 ± 1.5 in patients with subsequent fractures and -2.9 ± 1.6 in patients without subsequent fractures. The percentage of subsequent fractures was 13.9 % (10 of 72) for treated vertebrae located in non-thoracolumbar junction, and 26.2 % (27 of 103) in the thoracolumbar junction. Conclusion: The most important risk factors affecting subsequent fractures after vertebroplasty were osteoporosis and treated level at the thoracolumbar junction. © 2013 Springer-Verlag.
Zhao G.C.,Beijing Friendship Hospital
Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology | Year: 2012
Evaluating the accuracy and safety as well as the equivalence compared with the control kit of RIDA QUICK Norovirus detection kit(R-Biopharm, Germany). Based on the results of commercially available IDEA Norovirus detection kit (ELISA), the sensitivity and specificity and accuracy of RIDA QUICK Norovirus detection kit (immunochromatographic assay) were evaluated. The sensitivity and specificity of RIDA QUICK Norovirus detection kit were 98.4% and 92.4%, and the accuracy was 97.6% compared with the control kit. RIDA QUICK Norovirus detection kit has good sensitivity and specificity for the detection of norovirus antigens.
Zhu J.-G.,Beijing Friendship Hospital |
Zhang Z.-T.,Beijing Friendship Hospital
Journal of Laparoendoscopic and Advanced Surgical Techniques | Year: 2015
Background: Postcholecystectomy syndrome has been a long-standing source of frustration for surgeons. The objective of this study was to assess the feasibility and safety of laparoscopic remnant cholecystectomy (LRC) and laparoscopic transcystic common bile duct (CBD) exploration (LTCBDE) when adopted as the management for gallbladder/cystic duct remnant with stones and choledocholithiasis (GRSC) after cholecystectomy. Patients and Methods: This is a retrospective study of 11 patients who underwent surgeries for GRSC: the first 4 patients (Group 1) underwent open remnant cholecystectomy and CBD exploration, whereas the last 7 patients (Group 2) underwent LRC with LTCBDE successfully. Demographic data and perioperative parameters were analyzed and compared between the two groups. Results: All 11 patients had undergone cholecystectomy for symptomatic gallstone diseases. These patients had a mean age of 62 years. The time interval between cholecystectomy and the diagnosis of GRSC ranged from 4 years to 23 years (mean, 13 years). There was a significant reduction in postoperative hospital stay (5.00±1.41 versus 2.14±1.77 days, P=.034) and blood loss (35.00±10.00 versus 14.29±7.87mL, P=.011) in Group 2 compared with Group 1. The 30-day morbidity rate was 9.1%. At a mean follow-up of 24 months (range, 6-45 months), no symptoms had recurred, and no mortality was recorded in this study. Conclusions: LRC and LTCBDE for GRSC are safe and feasible and could be offered as a choice in centers performing advanced laparoscopic procedures. © Copyright 2015, Mary Ann Liebert, Inc.